Literature DB >> 33568400

Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcγRIIb on Liver Sinusoidal Endothelial Cells by Endocytosis.

James M Turman1, Alana M Cheplowitz1, Charu Tiwari1, Thushara Thomas1, Dhruvi Joshi1, Menakshi Bhat2, Qian Wu3, Erik Pong4, Seung Y Chu4, David E Szymkowski4, Amit Sharma3,5, Stephanie Seveau3, John M Robinson6, Jesse J Kwiek2, Dennis Burton7, Murugesan V S Rajaram3, Jonghan Kim8, Lars Hangartner7, Latha P Ganesan9.   

Abstract

Neutralizing Abs suppress HIV infection by accelerating viral clearance from blood circulation in addition to neutralization. The elimination mechanism is largely unknown. We determined that human liver sinusoidal endothelial cells (LSEC) express FcγRIIb as the lone Fcγ receptor, and using humanized FcγRIIb mouse, we found that Ab-opsonized HIV pseudoviruses were cleared considerably faster from circulation than HIV by LSEC FcγRIIb. Compared with humanized FcγRIIb-expressing mice, HIV clearance was significantly slower in FcγRIIb knockout mice. Interestingly, a pentamix of neutralizing Abs cleared HIV faster compared with hyperimmune anti-HIV Ig (HIVIG), although the HIV Ab/Ag ratio was higher in immune complexes made of HIVIG and HIV than pentamix and HIV. The effector mechanism of LSEC FcγRIIb was identified to be endocytosis. Once endocytosed, both Ab-opsonized HIV pseudoviruses and HIV localized to lysosomes. This suggests that clearance of HIV, endocytosis, and lysosomal trafficking within LSEC occur sequentially and that the clearance rate may influence downstream events. Most importantly, we have identified LSEC FcγRIIb-mediated endocytosis to be the Fc effector mechanism to eliminate cell-free HIV by Abs, which could inform development of HIV vaccine and Ab therapy.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33568400      PMCID: PMC7946731          DOI: 10.4049/jimmunol.2000772

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  64 in total

Review 1.  Antibodies, viruses and vaccines.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

Review 2.  Fc-receptors as regulators of immunity.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Adv Immunol       Date:  2007       Impact factor: 3.543

3.  Lectin intravital perfusion studies in tumor-bearing mice: micrometer-resolution, wide-area mapping of microvascular labeling, distinguishing efficiently and inefficiently perfused microregions in the tumor.

Authors:  P L Debbage; J Griebel; M Ried; T Gneiting; A DeVries; P Hutzler
Journal:  J Histochem Cytochem       Date:  1998-05       Impact factor: 2.479

4.  Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus.

Authors:  Holly M Horton; Seung Y Chu; Elizabeth C Ortiz; Erik Pong; Saso Cemerski; Irene W L Leung; Noam Jacob; Jonathan Zalevsky; John R Desjarlais; William Stohl; David E Szymkowski
Journal:  J Immunol       Date:  2011-02-28       Impact factor: 5.422

5.  The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population.

Authors:  Elizabeth S Russell; Jesse J Kwiek; Jessica Keys; Kirston Barton; Victor Mwapasa; David C Montefiori; Steven R Meshnick; Ronald Swanstrom
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

6.  The liver is a major organ for clearing simian immunodeficiency virus in rhesus monkeys.

Authors:  Linqi Zhang; Peter J Dailey; Agegnehu Gettie; Jim Blanchard; David D Ho
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  Fc receptors in liver sinusoidal endothelial cells in NZB/W F1 lupus mice: a histological analysis using soluble immunoglobulin G-immune complexes and a monoclonal antibody (2.4G2).

Authors:  S S Ahmed; H Muro; M Nishimura; I Kosugi; Y Tsutsi; H Shirasawa
Journal:  Hepatology       Date:  1995-07       Impact factor: 17.425

8.  Scavenger receptor B1, the HDL receptor, is expressed abundantly in liver sinusoidal endothelial cells.

Authors:  Latha P Ganesan; Jessica M Mates; Alana M Cheplowitz; Christina L Avila; Jason M Zimmerer; Zhili Yao; Andrei Maiseyeu; Murugesan V S Rajaram; John M Robinson; Clark L Anderson
Journal:  Sci Rep       Date:  2016-02-11       Impact factor: 4.379

9.  Association and dissociation of aggregated IgG from rat peritoneal macrophages.

Authors:  D W Knutson; A Kijlstra; L A Van Es
Journal:  J Exp Med       Date:  1977-05-01       Impact factor: 14.307

10.  Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies.

Authors:  M Sips; M Krykbaeva; T J Diefenbach; M Ghebremichael; B A Bowman; A-S Dugast; A W Boesch; H Streeck; D S Kwon; M E Ackerman; T J Suscovich; P Brouckaert; T W Schacker; G Alter
Journal:  Mucosal Immunol       Date:  2016-02-17       Impact factor: 7.313

View more
  3 in total

Review 1.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

2.  Stabilin receptors clear LPS and control systemic inflammation.

Authors:  Fatima Cabral; Mustafa Al-Rahem; John Skaggs; Thushara A Thomas; Naresh Kumar; Qian Wu; Paolo Fadda; Lianbo Yu; John M Robinson; Jonghan Kim; Ekta Pandey; Xinghui Sun; Wael N Jarjour; Murugesan V S Rajaram; Edward N Harris; Latha P Ganesan
Journal:  iScience       Date:  2021-10-25

3.  Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies.

Authors:  Jord C Stam; Steven de Maat; Dorien de Jong; Mathia Arens; Fenna van Lint; Lavina Gharu; Mark H van Roosmalen; Rob C Roovers; Nika M Strokappe; Ralf Wagner; Alexander Kliche; Hans J de Haard; Paul M van Bergen En Henegouwen; Monique Nijhuis; C Theo Verrips
Journal:  Sci Rep       Date:  2022-08-04       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.